The clinical development of therapeutic HPV vaccines, topical microbicides, and gene-editing platforms defines the future frontier of the Cervical Dysplasia Market. Unlike prophylactic vaccines that prevent initial infection, therapeutic vaccines stimulate cell-mediated T-cell immune responses to clear established high-risk HPV infections and regress dysplastic lesions non-surgically. In...